ASP 0819

Drug Profile

ASP 0819

Alternative Names: ASP0819

Latest Information Update: 27 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Class Analgesics
  • Mechanism of Action Calcium-activated potassium channel openers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fibromyalgia

Most Recent Events

  • 27 Feb 2018 Astellas Pharma completes a phase II trial in Fibromyalgia in USA (NCT03056690)
  • 01 Mar 2017 Astellas Pharma initiates enrolment in a phase II trial for Fibromyalgia in USA (NCT03056690)
  • 31 Jan 2017 Phase-II clinical trials in Fibromyalgia in USA (PO) (Astellas Pharma pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top